Kodak forms JV with NZ researchers for world’s first non-invasive digital imaging breast screening technique

The multi-national Eastman Kodak Company is forming a joint venture company with researchers at the University of Canterbury, to develop the world’s first non-invasive digital imaging breast screening technique. 

The new company will use Eastman Kodak’s photographic and imaging expertise to develop a technique researchers say could revolutionise breast screening services and significantly improve detection rates. 

The company will be based at the university’s Centre for Bioengineering which was officially opened this week. 

Its director, Professor Tim David, says the project with Eastman Kodak is expected to cost up to $12-million over 5 to 6 years. 

He says the new procedure, which is being developed by senior mechanical engineering lecturer Dr Geoff Chase and fellow mechanical engineering lecturer Dr Eli Van Houten, would do away with x-rays and focus on movement of tissue in the breast. 

Cancerous tissue is between 5 and 50 times stiffer than healthy tissue. The new procedure would use digital imaging to measure tissue stiffness while a small vibration was passed through it. 

“By looking at how the surface of the breast moves you’ll be able to understand what’s going on underneath by doing what’s called an inverse problem,” Professor David says. 

“That means by looking at how the tissue moves you can actually detect what’s underneath the skin in the tissue and if there are any tumours within that tissue. The movement of the skin will actually give you a clue as to how big that tumour is and where it is.”

Dr Chase and Dr Van Houten envisage the new procedure being more appealing to women and say the equipment would be compact and easily transportable to medical centres, particularly in remote areas. 

“One of the big advantages of this is everything we’re doing is non-invasive. There’s also no compression required and there’s no x-ray dose. These are all the things that women complain about and which cause lower compliance in mammography,” Dr Chase says. 

He is confident that the procedure could increase the chance of smaller tumours being detected and improve the survival rate of breast cancer sufferers. 

Another benefit would be the procedure’s use of computers and digital imaging technology. 

“As we all know computers get faster and as these computers and these digital imaging sensors get faster with higher resolution they will not only get cheaper, but we’ll be able to do better for the same kind of input. So we should improve naturally over time as the type of technology that underlies it improves.” 

Dr Chase says the multi-million dollar venture will be funded initially by the Ministry of Economic Development and the government’s science funding agency, the Foundation for Research, Science and Technology. 

About 10 post-graduate students will eventually be hired by the new company to work on the project. 

Dr Chase expects the company, which is yet to be named, will be operational by next month. 

For further information and to arrange interviews, please contact:

John MacDonald
Communications Manager
University of Canterbury

Tel: +64-3-364 2910
Fax: +64-3-364 2679
Mob: +64-27-441 7280
[email protected]

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Alzheimer's guidelines focus on risk, not diagnosis, in healthy adults